Screener
Celldex Therapeutics CLDX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(152,188) | $(110,396) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,756 | 1,740 |
| Amortization and premium of marketable securities, net | (2,328) | (3,955) |
| Loss on sale or disposal of assets | 4 | 6 |
| Stock-based compensation expense | 16,931 | 18,507 |
| Changes in operating assets and liabilities: |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's net income?
- Celldex Therapeutics (CLDX) reported net income of -$73.5M in Q2 2026.
- How has Celldex Therapeutics's net income changed year-over-year?
- Celldex Therapeutics's net income decreased by 29.9% year-over-year, from -$56.6M to -$73.5M.
- What is the long-term trend for Celldex Therapeutics's net income?
- Over 4 years (2021 to 2025), Celldex Therapeutics's net income has grown at a 38.4% compound annual growth rate (CAGR), from -$70.51M to -$258.76M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Celldex Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude